comparemela.com

Latest Breaking News On - Marios giannakis - Page 1 : comparemela.com

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers

CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Cancer rates are climbing among young people It s not clear why

Vanessa Chapoy had just turned 24 when she felt the lump in her breast. It was “huge,” she remembers, “like the size of a walnut, or a big marble.” She went to the first in a series of doctors that night to have it checked out. Two and a half weeks later, she was diagnosed…

Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI Cancers

Marios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.

New AI tool predicts colon cancer survival, t

New AI tool accurately predicts both overall survival and disease-free survival after colorectal cancer diagnosis.                                                                 The model uses visual markers on pathology images to glean insights into a tumor’s genomic profile and predicts tumor behavior, disease progression, treatment response. The new model could help augment clinical decision-making. Because the AI tool relies on images alone, it could be particularly valuable for hospitals lacking the technology or expertise to perform sophisticated genomic profiling of tumor tissues.

Model Provides Actionable Insights for Physicians to Augment Clinical Decisions

Model Provides Actionable Insights for Physicians to Augment Clinical Decisions
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.